Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 (Abraxane) Weekly in Taxol-Resistant Metastatic Breast Cancer
NCT00046514Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2001
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in breast cancer, sponsored by Celgene Corporation. Primary endpoints: Safety, Tolerability and 1 more. Started Jun 2001; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00046514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046514.